在基因甲基化向治疗中的作用机制和耐药性
Makoto Yamagishi1,2, Yuta Kuze3, Seiichiro Kobayashi4,5
1Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. myamagishi@edu.k.u-tokyo.ac.jp.
Nature
|February 21, 2024
概括
通过改变染色质结构,Valemetostat是一种EZH1- EZH2抑制剂,在成年T细胞白血病/ 淋巴瘤中缩小瘤并显示持久反应. 通过突变或DNA甲基化出现抗药性,突显了持续的表观遗传癌症治疗的需要.
科学领域:
- 癌症学
- 表观遗传学
- 分子生物学
背景情况:
- 表观遗传失调,特别是素H3 lysine三甲基化 (H3K27me3),在癌症中提供治疗点.
- 针对H3K27me3的疗法和瘤细胞反应的确切机制尚不完全理解.
研究的目的:
- 在成年T细胞白血病/ 淋巴瘤 (ATLL) 中研究valemetostat,一种EZH1- EZH2双抑制剂的疗效,作用机制和耐药性.
- 阐明导致治疗耐药性的表观遗传和遗传变化.
主要方法:
- 在有侵袭性淋巴瘤的患者中对valemetostat的临床试验.
- 综合性单细胞分析以评估染色体结构和基因表达.
- 基因组分析以确定与耐药性相关的突变.
主要成果:
- 在患有ATLL的患者中,Valemetostat表现出强烈的抗瘤活性,减少瘤大小并产生持久的反应.
- 这种药物破坏了缩的染色质, 并中和了关键基因位点,
- 通过PRC2突变或TET2突变/DNMT3A过度表达而形成的耐药性,通过DNA甲基化导致染色体重凝.
- 在获得耐药性之前,有独特的代谢和转化特征的不同亚群被确定为易受感染.
结论:
- 通过向H3K27me3, 瓦莱梅托斯塔特显示为一种有前途的治疗药物.
- 了解抗性机制,包括PRC2突变和DNA甲基化途径,对于开发持续的表观遗传癌症疗法至关重要.
- 针对表观遗传驱动因素和染色质平衡提供了更有效和更持久的癌症治疗途径.
相关概念视频
Histone Modification
13.3K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.3K
Spreading of Chromatin Modifications
8.3K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.3K
Phase II Reactions: Methylation Reactions
187
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
187
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


